Eton Pharmaceuticals, Inc. (ETON)

Market Cap	507.66M
Revenue (ttm)	48.33M
Net Income (ttm)	-4.58M
Shares Out	26.82M
EPS (ttm)	-0.18
PE Ratio	n/a
Forward PE	36.76
Dividend	n/a
Ex-Dividend Date	n/a

Volume	400,140
Open	19.62
Previous Close	19.70
Day's Range	18.82 - 20.19
52-Week Range	3.18 - 18.41
Beta	1.23
Analysts	Strong Buy
Price Target	29.00 (+53.2%)
Earnings Date	May 13, 2025

About ETON

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-s...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 13, 2018
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: ETON
• Website: https://www.etonpharma.com

Financial Performance

In 2024, Eton Pharmaceuticals's revenue was $39.01 million, an increase of 23.29% compared to the previous year's $31.64 million. Losses were -$3.82 million, 308.4% more than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for ETON stock is "Strong Buy." The 12-month stock price forecast is $29.0, which is an increase of 53.20% from the latest price.

Price Target

$29.0

(53.20% upside)

Analyst Consensus: Strong Buy